23rd Dec 2008 07:00
23 December 2008
HENDERSON MORLEY PLC
(AIM: HML)
Koi Vaccine Update
The Board of Henderson Morley announces that further to the Chairman's statement which accompanied the results for the full year, the initial phase of the field studies has now been completed.
The vaccine candidates under examination were formulated to give a wide range of doses, using proprietary adjuvants (compounds that help boost and increase the duration of immune responses). The results from the study have demonstrated that the vaccine candidates were safe and well tolerated, with adverse effects no greater than unvaccinated controls.
Fish were vaccinated and examined, amongst other parameters, for immune responses to vaccination, vaccination dose, vaccination safety and assessment of the safety and immunogenicity of the new adjuvant. The studies have given a much greater understanding of immune responses and dose requirements. It is likely that from the next phase of studies, due to start in Jan 2009, a final vaccine candidate will be selected.
Commenting on the announcement, Andrew Knight, Henderson Morley Executive Chairman said: "This is an important first stage in studying the efficacy of the KHV vaccine. We can now move forwards to the next phase of the study which we anticipate will start in early January 2009."
---ENDS---
ENQUIRIES:
HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
Maxine Barnes
Nick Rome
BREWIN DOLPHIN INVESTMENT BANKING 0113 241 0126
Neil Baldwin
HYBRIDAN LLP 0203 159 5085
Claire Noyce/Stephen Austin
Further information on Henderson Morley plc can be accessed through the Company's website at www.henderson-morley.com
Related Shares:
HML.L